Empowering Precision Diagnostics
Bringing ImmunoGuide ELISA technologies to Europe and beyond
Validated ELISA kits for therapeutic drug monitoring and anti-drug antibody detection, for clinical labs, research institutions, and biotech teams. For Research Use Only.
Featured ELISA kits
Drug-level and anti-drug antibody assays across TNF-alpha, VEGF, EGFR, HER2, and more.
ADALIMUMAB ELISA
Analyte: Adalimumab
View kitADALIMUMAB ELISA (MAB-BASED)
Analyte: Adalimumab
View kitAFLIBERCEPT ELISA
Analyte: Aflibercept
View kitANTIBODY TO ADALIMUMAB ELISA
Analyte: Adalimumab
View kitANTIBODY TO BEVACIZUMAB ELISA
Analyte: Bevacizumab
View kitANTIBODY TO CERTOLIZUMAB PEGOL ELISA
Analyte: Certolizumab Pegol
View kitFrom our journal
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, and assay validation.
Rituximab Biosimilars in AAV: What Six-Month Real-World Data Tell Monitoring Scientists
The BRAVO multicenter cohort study found no statistically significant differences in remission rates, relapse rates, or serious adverse events between biosimilar and originator rituximab at six months in granulomatosis with polyangiitis and microscopic polyangiitis. For laboratories supporting drug-level and immunogenicity testing in biosimilar-treated AAV populations, the findings reinforce rather than reduce the case for structured pharmacokinetic and pharmacodynamic monitoring. B cell depletion kinetics, ANCA serology, serum drug levels, and anti-drug antibody assays each remain indispensable endpoints regardless of which rituximab formulation the patient receives.
Atypical Carry-Over in a Gyrolab ADA Assay: Lessons from a Rituximab Biosimilar Case Study
A published case study targeting MabionCD20, a rituximab biosimilar, identified wave-like signal fluctuations in Gyrolab-based ADA assays caused by neutralization buffer chemistry and fluorophore-induced isoelectric point shifts. The investigation offers transferable troubleshooting principles for any laboratory running Gyrolab-based immunogenicity programs, particularly around drug tolerance and repeatability.
What "Highly Similar" Actually Requires: Analytical Methods for mAb Biosimilar Characterization
Regulatory approval of mAb biosimilars now depends less on replicating clinical trial results and more on high-resolution analytical characterization. A 2026 BioDrugs review of successful US and EU dossiers maps the assay strategies that matter, while the FDA's September 2025 waiver of a clinical efficacy study for a ustekinumab biosimilar makes the principle concrete for immunoassay and TDM scientists.